Clinical observations support this hypothesis: among cancer patients undergoing allogeneic bone marrow transplantation, those exhibiting stronger IL-4 responses experience significantly less severe GVHD compared to individuals with weaker responses [154]. Here, IL4 is linked to graft versus host disease.